PATENT CLAIM ANALYSIS

Application Number: 15885231
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["514", "464000"]

Abstract:
The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Claim (Index 13):
The tablet composition of  claim 1 , wherein the neuro-attenuating ketamine achieves a combined concentration of ketamine and its metabolite norketamine in plasma in the range of 10-500 ng/ml, and maintains this concentration for duration of the release period.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 86.0
- Lexical Diversity: 1.80357
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14914416', '15524224', '15728695', '15304613', '14974576']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7718160048532141
- 35 USC 102 Novelty (BERT): 0.6068714522852151
- Combined Prediction Score: 0.7553215495964142
- Mean Citation Score: 323.11179
- Max Citation Score: 517.1948
- Similarity Product: 508.7226805431842

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test